Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. TransCode Therapeutics Inc’s current trading price is -97.59% away from its 52-week high, while its distance from the 52-week low is 117.13%. The stock’s price range during this period has varied between $0.22 and $19.42. The company, active in the Healthcare sector, saw a trading volume of around 0.56 million for the day, considerably lower average daily volume of 1.7 million observed over the last three months.
TransCode Therapeutics Inc’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $19.42 on 11/08/23, with the lowest value being $0.22 on 08/14/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
TransCode Therapeutics Inc (RNAZ) has experienced a quarterly rise of 81.50% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 8.10M and boasts a workforce of 10 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.5300, with a change in price of -0.7310. Similarly, TransCode Therapeutics Inc recorded 1,549,603 in trading volume during the last 100 days, posting a change of -60.92%.
How RNAZ’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for RNAZ stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.00.
RNAZ Stock Stochastic Average
As of today, the raw stochastic average of TransCode Therapeutics Inc over the last 50 days is at 42.67%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 4.72%. Further, the company’s Stochastic %K and %D values for the last 20 days were 16.00% and 19.40%, respectively.
RNAZ Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price loss of -92.89% this year. Over the last six months, there has been a stronger performance of -54.02%. The price of RNAZ leaped by -2.76% during the last 30 days period. For the last 5-days stocks have slided -6.94%.
